What breast cancer patients really think about their treatment
NCT ID NCT07008963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib + fulvestrant for at least one week. The goal was to learn about their attitudes, experiences, and any side effects related to the treatment schedule. No new drugs were given; it was purely an observational study to gather patient feedback.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Redwood Shores, California, 94065, United States